Dr. Barry Horowitz, M.D
NPI: 1437163003
Total Payments
$991,672
2024 Payments
$69,505
Companies
73
Transactions
1,950
Medicare Patients
62,466
Medicare Billing
$2.4M
Payment Breakdown by Category
Other$745,813 (75.2%)
Research$118,712 (12.0%)
Consulting$56,315 (5.7%)
Travel$37,343 (3.8%)
Food & Beverage$32,095 (3.2%)
Gifts$1,208 (0.1%)
Education$185.97 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $732,163 | 589 | 73.8% |
| Unspecified | $118,712 | 19 | 12.0% |
| Consulting Fee | $56,315 | 23 | 5.7% |
| Travel and Lodging | $37,343 | 276 | 3.8% |
| Food and Beverage | $32,095 | 1,019 | 3.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $11,900 | 6 | 1.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,750 | 2 | 0.2% |
| Gift | $1,208 | 5 | 0.1% |
| Education | $185.97 | 11 | 0.0% |
Payments by Type
General
$872,961
1,931 transactions
Research
$118,712
19 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $494,471 | 800 | $0 (2024) |
| Novo Nordisk Inc | $178,703 | 301 | $0 (2024) |
| Eli Lilly and Company | $121,027 | 31 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $73,051 | 155 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $33,729 | 53 | $0 (2020) |
| Amgen Inc. | $19,687 | 70 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $18,307 | 49 | $0 (2021) |
| ABBVIE INC. | $13,384 | 50 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $11,152 | 17 | $0 (2019) |
| Esperion Therapeutics, Inc. | $6,928 | 7 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $69,505 | 204 | Lilly USA, LLC ($55,334) |
| 2023 | $89,566 | 230 | Lilly USA, LLC ($72,061) |
| 2022 | $95,299 | 217 | Lilly USA, LLC ($69,467) |
| 2021 | $95,779 | 198 | Lilly USA, LLC ($64,465) |
| 2020 | $73,295 | 187 | Lilly USA, LLC ($44,767) |
| 2019 | $173,952 | 322 | Lilly USA, LLC ($84,637) |
| 2018 | $211,526 | 279 | Eli Lilly and Company ($67,028) |
| 2017 | $182,751 | 313 | Lilly USA, LLC ($61,397) |
All Payment Transactions
1,950 individual payment records from CMS Open Payments — Page 1 of 78
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $24.75 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/20/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $7.12 | General |
| Category: Diabetes Care | ||||||
| 12/16/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $900.00 | General |
| Category: Diabetes | ||||||
| 12/16/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $18.44 | General |
| Category: Endocrinology | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $21.97 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/10/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $17.86 | General |
| Category: Cardio-renal | ||||||
| 12/04/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug), SYNJARDY | Food and Beverage | In-kind items and services | $32.25 | General |
| Category: DIABETES | ||||||
| 12/04/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $17.66 | General |
| Category: Endocrinology | ||||||
| 12/03/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $9.70 | General |
| Category: Diabetes Care | ||||||
| 12/02/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $8.10 | General |
| Category: Diabetes | ||||||
| 11/26/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $17.73 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/25/2024 | Radius Health, Inc. | Tymlos (Drug) | Food and Beverage | In-kind items and services | $22.30 | General |
| Category: Endocrinology | ||||||
| 11/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug), SYNJARDY | Food and Beverage | In-kind items and services | $19.79 | General |
| Category: DIABETES | ||||||
| 11/21/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $9.50 | General |
| Category: Diabetes | ||||||
| 11/20/2024 | Amneal Pharmaceuticals LLC | UNITHROID (Drug) | Food and Beverage | In-kind items and services | $23.56 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/19/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Travel and Lodging | Cash or cash equivalent | $60.30 | General |
| Category: Diabetes | ||||||
| 11/18/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Diabetes | ||||||
| 11/18/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,125.00 | General |
| Category: Diabetes | ||||||
| 11/18/2024 | Verity Pharmaceuticals Inc. | Tlando (Drug) | Food and Beverage | Cash or cash equivalent | $19.66 | General |
| Category: Testosterone Replacement Therapy (TRT) | ||||||
| 11/13/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $118.67 | General |
| Category: Diabetes | ||||||
| 11/13/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $21.54 | General |
| 11/12/2024 | Insulet Corporation | Omnipod (Device) | Food and Beverage | Cash or cash equivalent | $25.98 | General |
| Category: Insulin Pump | ||||||
| 11/12/2024 | Insulet Corporation | Omnipod (Device) | Food and Beverage | Cash or cash equivalent | $23.49 | General |
| Category: Insulin Pump | ||||||
| 11/07/2024 | PFIZER INC. | SOMAVERT (Drug), GENOTROPIN | Food and Beverage | In-kind items and services | $24.69 | General |
| Category: ENDOCRINE DISEASE;METABOLIC DISEASE | ||||||
| 11/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $32.67 | General |
| Category: DIABETES | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO WITH AN OPEN-LABEL POSTPRANDIAL LY900014 TREATMENT GROUP, IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC, IN ADULTS WITH TYPE 1 DIABETES PRONTO-T1D | Eli Lilly and Company | $88,581 | 4 |
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO HUMALOG IN ADULTS WITH TYPE 1 DIABETES USING CONTINUOUS SUBCUTANEOUS INSULIN INFUSION | Eli Lilly and Company | $8,678 | 1 |
| A STUDY OF LY3209590 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $7,422 | 3 |
| A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | Eli Lilly and Company | $5,392 | 1 |
| A PROSPECTIVE, RANDOMIZED, DOUBLE BLIND COMPARISON OF LY900014 AND FIASP, BOTH IN COMBINATION WITH BASAL INSULIN IN ADULTS WITH TYPE 1 DIABETES PROTO COMPARE | Eli Lilly and Company | $5,175 | 1 |
| A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) | Eli Lilly and Company | $1,270 | 2 |
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | Eli Lilly and Company | $530.01 | 1 |
| AN EARLY FEASIBILITY STUDY TO EVALUATE THE SAFETY AND FUNCTIONALITY OF AN INDIVIDUAL ACCRUING DATA ALGORITHM WITH LY3209590 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $507.00 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-2) | Eli Lilly and Company | $446.00 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) | Eli Lilly and Company | $412.28 | 2 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-2) | Eli Lilly and Company | $198.36 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) | Eli Lilly and Company | $99.34 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 52 | 10,322 | 22,570 | $1.4M | $529,943 |
| 2022 | 67 | 16,080 | 34,991 | $1.5M | $580,542 |
| 2021 | 76 | 18,287 | 40,520 | $1.7M | $666,981 |
| 2020 | 80 | 17,777 | 34,414 | $1.6M | $577,558 |
Total Patients
62,466
Total Services
132,495
Medicare Billing
$2.4M
Procedure Codes
275
All Medicare Procedures & Services
275 procedure records from CMS Medicare Utilization — Page 1 of 11
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 784 | 1,896 | $388,687 | $178,171 | 45.8% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 105 | 738 | $73,800 | $35,872 | 48.6% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 145 | 721 | $86,520 | $27,265 | 31.5% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2023 | 289 | 300 | $67,434 | $26,304 | 39.0% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 653 | 1,320 | $63,518 | $21,697 | 34.2% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 94 | 482 | $53,020 | $18,295 | 34.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 136 | 136 | $43,207 | $16,732 | 38.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 890 | 1,992 | $19,914 | $16,720 | 84.0% |
| 82985 | Glycated protein level | Office | 2023 | 372 | 959 | $41,396 | $15,730 | 38.0% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 502 | 1,171 | $44,931 | $15,350 | 34.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 172 | 233 | $31,716 | $14,776 | 46.6% |
| 86141 | Measurement c-reactive protein for detection of infection or inflammation, high sensitivity | Office | 2023 | 462 | 1,071 | $39,701 | $13,578 | 34.2% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 573 | 1,302 | $78,080 | $13,465 | 17.2% |
| 82306 | Vitamin d-3 level | Office | 2023 | 230 | 340 | $27,200 | $9,863 | 36.3% |
| 84378 | Carbohydrate analysis, single quantitative | Office | 2023 | 347 | 826 | $33,040 | $9,323 | 28.2% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 117 | 307 | $26,482 | $8,310 | 31.4% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2023 | 231 | 542 | $21,680 | $8,011 | 37.0% |
| 84436 | Thyroxine (thyroid chemical), total | Office | 2023 | 528 | 1,039 | $25,975 | $6,980 | 26.9% |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | Office | 2023 | 65 | 158 | $15,800 | $6,975 | 44.1% |
| 84479 | Thyroid hormone evaluation | Office | 2023 | 527 | 1,038 | $20,760 | $6,569 | 31.6% |
| 83970 | Parathormone (parathyroid hormone) level | Office | 2023 | 94 | 152 | $17,972 | $6,148 | 34.2% |
| 82044 | Urine microalbumin (protein) analysis | Office | 2023 | 427 | 1,001 | $17,017 | $6,110 | 35.9% |
| 82570 | Creatinine level to test for kidney function or muscle injury | Office | 2023 | 428 | 1,002 | $15,030 | $5,085 | 33.8% |
| 84481 | Thyroid hormone, t3 measurement, free | Office | 2023 | 148 | 231 | $10,404 | $3,835 | 36.9% |
| 82948 | Blood glucose (sugar) measurement using reagent strip | Office | 2023 | 338 | 755 | $4,530 | $3,725 | 82.2% |
About Dr. Barry Horowitz, M.D
Dr. Barry Horowitz, M.D is a Endocrinology, Diabetes & Metabolism healthcare provider based in West Palm Beach, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1437163003.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Barry Horowitz, M.D has received a total of $991,672 in payments from pharmaceutical and medical device companies, with $69,505 received in 2024. These payments were reported across 1,950 transactions from 73 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($732,163).
As a Medicare-enrolled provider, Horowitz has provided services to 62,466 Medicare beneficiaries, totaling 132,495 services with total Medicare billing of $2.4M. Data is available for 4 years (2020–2023), covering 275 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location West Palm Beach, FL
- Active Since 07/28/2006
- Last Updated 03/15/2023
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1437163003
Products in Payments
- TRULICITY (Drug) $206,438
- MOUNJARO (Drug) $172,820
- HUMULIN (Drug) $71,440
- FARXIGA (Drug) $57,518
- Ozempic (Drug) $42,059
- Tresiba (Drug) $41,978
- INVOKANA (Drug) $33,729
- LYUMJEV (Drug) $26,900
- Rybelsus (Drug) $24,611
- Victoza (Drug) $21,528
- RYBELSUS (Drug) $20,751
- Repatha (Biological) $19,094
- CYCLOSET (Drug) $16,670
- BYDUREON (Drug) $15,502
- Xultophy 100/3.6 (Drug) $7,857
- ARMOUR THYROID (Drug) $7,665
- STEGLATRO (Drug) $7,311
- JANUVIA (Drug) $7,303
- NEXLIZET (Drug) $6,914
- Androgel (Drug) $5,203
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in West Palm Beach
William Kaye, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $541,803
Endocrinology, Diabetes & Metabolism $541,803
Dr. Geetanjali Kale, Mbbs, MBBS
Endocrinology, Diabetes & Metabolism — Payments: $19,378
Endocrinology, Diabetes & Metabolism $19,378
Dr. Sharon Miller, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $15,650
Endocrinology, Diabetes & Metabolism $15,650
Kort Knudson, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $11,488
Endocrinology, Diabetes & Metabolism $11,488
Alexis Da Silva, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $10,863
Endocrinology, Diabetes & Metabolism $10,863
Morolake Amole, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $8,876
Endocrinology, Diabetes & Metabolism $8,876